8910 related articles for article (PubMed ID: 12903626)
1. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma.
Fabbri M; Ridolfi R; Maltoni R; Ridolfi L; Riccobon A; Flamini E; De Paola F; Verdecchia GM; Amadori D
Tumori; 2000; 86(1):46-52. PubMed ID: 10778766
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G
Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658
[TBL] [Abstract][Full Text] [Related]
10. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
11. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
[TBL] [Abstract][Full Text] [Related]
12. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
13. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B
Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma.
Ratto GB; Zino P; Mirabelli S; Minuti P; Aquilina R; Fantino G; Spessa E; Ponte M; Bruzzi P; Melioli G
Cancer; 1996 Jul; 78(2):244-51. PubMed ID: 8673999
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]